key: cord-1010396-zb3gzcmh
authors: Liu, Qianyun; Xiong, Qing; Mei, Fanghua; Ma, Chengbao; Zhang, Zhen; Hu, Bing; Xu, Junqiang; Jiang, Yongzhong; Zhan, Faxian; Zhou, Suhua; Tao, Li; Chen, Xianying; Guo, Ming; Wang, Xin; Fang, Yaohui; Shen, Shu; Liu, Yingle; Liu, Fang; Zhou, Li; Xu, Ke; Ke, Changwen; Deng, Fei; Cai, Kun; Yan, Huan; Chen, Yu; Lan, Ke
title: Antibody neutralization to SARS-CoV-2 and variants after one year in Wuhan, China
date: 2021-11-03
journal: Innovation (N Y)
DOI: 10.1016/j.xinn.2021.100181
sha: 89940cdaf74799bca32a71de9b0f54c8413fd446
doc_id: 1010396
cord_uid: zb3gzcmh

Most COVID-19 convalescents can build effective anti-SARS-CoV-2 humoral immunity, but it remains unclear how long it can maintain and how efficiently it can prevent the reinfection of the emerging SARS-CoV-2 variants. Here, we tested the sera from 248 COVID-19 convalescents around one year post-infection in Wuhan, the earliest known epicenter. SARS-CoV-2 immunoglobulins G (IgG) were well maintained in most patients and potently neutralizes the infection of the original strain and the B.1.1.7 variant. However, varying degrees of immune escape was observed on the other tested variants in a patient-specific manner, with individuals showing remarkably broad neutralization potency. The immune escape can be largely attributed to several critical spike mutations. These results suggest that SARS-CoV-2 can elicit long-lasting immunity but escaped by the emerging variants.

The SARS-CoV-2 emerged more than a year ago rapidly swept across the world and developed into a long-lasting COVID-19 pandemic with devastating impacts. [1] [2] [3] The situation leads to the perpetual mutation of SARS-CoV-2 with numerous variants emerging around the world. In addition to the initial D614G mutation, the viral spike protein undergone antigenic drift and produced several variants of concern associated with local outbreaks, such as B.1.1.7 (Alpha), 4 

Most COVID-19 patients can build anti-SARS-CoV-2 humoral immunity against SARS-CoV-2 after recovery. 9, 10 However, due to the lack of sufficient evidence about how long the protective immunity induced by prior infection or vaccination can maintain, the optimal interval between the vaccinations remains to be determined. [11] [12] [13] Additionally, increasing evidence showing these variants of concern, especially the B.1.617.2 and B.1.351, [14] [15] [16] [17] [18] [19] [20] remarkably increased resistance to the neutralizing antibodies, which largely due to the mutations in the RBD region interacting with human angiotensin-converting enzyme 2 (hACE2). 1 It is imperative to figure out the durability and breadth of SARS-CoV-2 neutralizing antibodies elicited by previous infection or vaccination based on the original strain.

Wuhan is the first known epicenter of the SARS-CoV-2 outbreak. Almost all patients in this city were infected by the original strain before the city reopen and the epidemic here had been well controlled thereafter before the emergence of variants. 21, 22 In this study, sera from convalescents infected around one year ago in Wuhan were collected to investigate the SARS-CoV-2 antibody durability and the breadth over time.

Results from Enzyme-linked immunosorbent assay (ELISA) and pseudovirus neutralization assay demonstrated that the SARS-CoV-2 RBD-specific IgG antibodies remain detectable in most patients, which potently inhibit the infection of the SARS- Co., Ltd), which is based on the competition between the neutralizing antibodies in sera and ACE2 to horseradish peroxidase labeled RBD protein (HRP-RBD). These ELISA detections were applied following the manufacturer's instructions. following the manufacturer's instructions.

The pseudovirus packaged with spike proteins from the WT SARS-CoV-2 and the SARS-CoV-2 variants were produced according to a published protocol with minor modifications. 24 Briefly, Vero-E6 cells were transfected with plasmids expressing 

The SARS-CoV-2 pseudoviruses (3×10 5 TCID50/well) were incubated with serialdiluted sera at room temperature for 30 mins in 96-well white flat-bottom culture plates and then mixed with trypsinized BHK-21-hACE2 cells with the density of 2×10 4 /well. After 16 hrs, the medium of the infected cells was removed, and the cells were lysed with 1× Bright-Glo Luciferase Assay reagent (Promega) for chemiluminescence detection with a SpectraMax iD3 Multi-well Luminometer (Molecular devices). The 50 % neutralization dilution titer (NT50) was calculated by GraphPad Prism 7 software with nonlinear regression curve fitting (normalized response, variable slope).

The SARS-CoV-2 WT strain (IVCAS 6.7512) and B. 

Data are presented as mean values with s.e.m. or s.d.. All statistical analyses were done using GraphPad Prism 7. Differences between two independent samples were J o u r n a l P r e -p r o o f evaluated by two-tailed Mann-Whitney U-tests, and P < 0.05 is considered statistically significant. Differences between two related samples were evaluated by paired twotailed t-tests.

To evaluate the durability and neutralizing activity of SARS-CoV-2 antibodies after infection, we collected sera and clinical records from 248 COVID-19 patients (Table S1 ). Conventional ELISA assays were then conducted to determine the anti-RBD IgG level and the competitive ability of ACE2 to RBD-binding of the sera.

As we set OD450=0.31 (the mean OD450 value + 3 SD of uninfected people's sera) as the cut-off value, 91 % (225/248) tested positive for anti-SARS-CoV-2-RBD IgG ( Figure 1A) . Our results also showed that the competitive ability is highly consistent with the anti-RBD IgG level (Figure 1A-1E, Table S1 ), indicating most RBD-targeting antibodies in the patients can interfere with the interaction between ACE2 and RBD.

However, the anti-RBD IgG level and the neutralizing activity of the sera showed no statistically significant difference in patients with different severity (Figure 1A and 1B) , J o u r n a l P r e -p r o o f gender (Figure 1C) , and age ( Figure 1E ) except for the higher sera competitive ability of ACE2 to RBD binding was found in female ( Figure 1D ).

The neutralizing activities of the sera were tested with SARS-CoV-2 pseudovirus Figure 1F by the pseudoviruses of four variants, with the WT-D614G as a control (Figure 2A) . When tested at 100-fold dilution, the mean neutralization efficiency of the sera against WT-D614G is 65 %. However, the efficiency reduced to 59 % for B. Figure 2B) . Interestingly, we found that a small fraction of the patients Kappa) variant, respectively. We tested the neutralizing activity of the 180 sera by these mutants with the WT-D614G as a control. As shown in Figure 2F , when tested at 100-fold dilution, the mean neutralization efficiency of the sera against WT-D614G is 69 %. However, the efficiency reduced to 61 % for L452R, 55 % for K417N, 54 % for E484K, and 52 % for L452R/E484Q. This result indicates that the RBD mutations are responsible for the reduction of cross-variant neutralization among the variants of concern.

To confirm whether the neutralization results are consistent between the SARS-CoV-2 pseudovirus and the authentic virus, we first conducted the authentic SARS-CoV-2 virus (WT) neutralization assay to verify the 30 representative sera showing high, medium, and low neutralizing activities in Figure 1F , respectively. The SARS-CoV-2 nucleocapsid (N) protein immunofluorescence assay showed consistent results with the pseudovirus neutralization assay (Figure 3A) .

We further verified the neutralizing activity of two groups of patients in Figure   2C and 2D (relatively resistant and relatively sensitive) by four authentic SARS-CoV- The sera were diluted 100-fold, pre-incubated with these viruses, and then applied to Vero E6 cells for infection neutralization assay. As shown in Figure 3B Figure 3C) . Again, these results are also consistent with the results from pseudovirus neutralization assays.

Previous studies show the protective immunity against seasonal coronaviruses (HCoV-NL63, HCoV-229E, HCoV-OC43 and HCoV-HKU1) may last only 6 to 12 months, 30 and the titer of SARS-CoV-2 antibody has been reported to decline rapidly in the first several months, 11 raising the concern about the durability of SARS-CoV-2 neutralizing antibodies elicited by either previous infection or vaccination. Additionally, SARS-CoV-2 variants are constantly emerging during the COVID-19 pandemic, greatly challenging the development and application of effective neutralizing antibodies and vaccines. 31, 32 It is imperative to investigate the durability and breadth of the anti-SARS-CoV-2 humoral immunity. To this end, we collected convalescent sera in Wuhan in consideration of the several unique advantages over the samples collected elsewhere: Firstly, we report that the effective neutralizing antibodies against SARS-CoV-2 could last at least one year in most COVID-19 convalescents without vaccination. Our results indicate that most people including asymptomatic and elderly patients could build and maintain effective anti-SARS-CoV-2 humoral immunity, with a few exceptions in each group for unknown reasons (Figure 1) . We speculate this phenotype might be attributed to the individual immune difference that deserves further study.

Another particular concern is the breadth of the anti-SARS-CoV-2 humoral immunity. Our study provides additional evidence that most sera collected from Figure S1 . The neutralizing activity of the convalescents' sera to WT-D614G and variants for NT50 determination Convalescents' sera were serially diluted and then were inoculated with 3×10 5 TCID50 pseudoviruses as indicated for 30 min at room temperature. BHK-21-hACE2 cells were infected by this mixture, followed by a chemiluminescence detection after 16 hrs. Mean ± s.d. (n=2) are shown. The NT50 was calculated by GraphPad Prism 7 software with nonlinear regression curve fitting (normalized response, variable slope). The horizontal dotted lines on each graph indicate 50 % and 0 % neutralization.

Table S1. The clinical records and sera reactivity to SARS-CoV-2 of the convalescents in this study.

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Public health actions to control new SARS-CoV-2 variants

RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak. Emerging microbes & infections 9

Investigation of novel SARS-CoV-2 variant: Variant of Concern 202012/01

Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa

Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings

High prevalence of SARS-CoV-2 B.1.1.7 (UK variant) and the novel B.1.5.2.5 lineage in Oyo State

Isolation and characterization of the new SARS-CoV-2 variant in travellers from the United Kingdom to India: VUI-202012/01 of the B.1.1.7 lineage

Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals

Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19

SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans

Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study

Distinct durability of IgM/IgG antibody responses in COVID-19 patients with differing severity

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

SARS-CoV-2 variants B.1.351 and P.1 escape J o u r n a l P r e -p r o o f from neutralizing antibodies

Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351

A recombinant receptor-binding domain in trimeric form generates protective immunity against SARS-CoV-2 infection in nonhuman primates. The Innovation 2, 100140

Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China

Modeling the Epidemic Trend of the 2019 Novel Coronavirus Outbreak in China. The Innovation 1

Comparison of vesicular stomatitis virus pseudotyped with the S proteins from a porcine and a human coronavirus

Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay

A note on some points of calculation method of LD50 by Reed and Muench

A Case of New Variant COVID-19 First Emerging in South Africa Detected in Airplane Pilot

Acquisition of the L452R mutation in the ACE2-binding interface of Spike protein triggers recent massive expansion of SARS-Cov-2 variants. bioRxiv : the preprint server for biology

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Seasonal coronavirus protective immunity is short-lasting

BNT162b2-elicited neutralization of B.1.617 and other SARS

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

China NSFC projects (32041007, 32070160 and 82041004), Fundamental Research Funds for the Central Universities (2042021kf0220 and 2042020kf0024), the Advanced Customer Cultivation Project of Wuhan National Biosafety Laboratory (2021ACCP-MS10) and Special Fund for COVID-19 Research

conceptualized the study design

Supplemental Information includes one figure and one table

Sera from a large cohort of COVID-19 convalescents in Wuhan were collected for evaluation of anti-SARS-CoV-2 humoral immunity

IgG were well maintained for one year in most convalescents and can potently neutralizes the original strain and the B.1.1.7 variant

Varying degrees of immune escape was observed on the tested variants

Sera from a few individuals showed remarkably broad neutralization potency against SARS-CoV-2 WT and variants

Overall, our study suggests that the timely update of the vaccines rather than the durability of the SARS-CoV-2 humoral immunity should be more of our concern.